Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.

Welcome to Supreme Court Opinions. In this episode, you’ll hear the Court’s opinion in Hikma Pharmaceuticals USA Inc. v Amarin Pharma, Inc.In this case, the court considered these issues.1. When a generic drug manufacturer excludes a patented use from its label, can it still be liable for inducing infringement if it calls its product a “generic version” of the brand-name drug and cites publicly available information about the brand-name drug’s sales?2. Can a patent infringement complaint survive dismissal if it does not allege that the defendant made any statement specifically instructing or encouraging the patented use?The case was decided on June 4, 2026. The opinion is presented here in its entirety, but with citations omitted. If you appreciate this episode, please subscribe. Thank you.